Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, M42, a global health champion powered by AI, technology and genomics and PureHealth, the largest healthcare group in the Middle ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

Children suffering from Spinal Muscular Atrophy (SMA) – a rare but debilitating genetic condition – are being denied a simple ...

Treatment with salanersen slowed neurodegeneration and improved motor function in children with SMA in a Phase 1 trial, interim results show.

Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim ...

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once ...

Spinal Muscular Atrophy known as SMA is a rare genetic disease that affects 1 in 6,000 children. And, tonight, the parents of 6 month old baby Emiliano Flores are calling out for help for their son.

The Syrian girl suffers from spinal muscular atrophy, a rare and serious genetic disorder that affects muscle strength and ...

In a Phase I study, previously treated pediatric SMA patients exhibited reductions in a marker of neurodegeneration after salanersen treatment.

Biogen plans to advance an experimental treatment for the neuromuscular disease spinal muscular atrophy, or SMA, into registrational studies following encouraging results from an early-stage trial.